Εμφανίζονται 1 - 20 Αποτελέσματα από 29 για την αναζήτηση '"ФАКТОРЫ НЕБЛАГОПРИЯТНОГО ПРОГНОЗА"', χρόνος αναζήτησης: 0,80δλ Περιορισμός αποτελεσμάτων
  1. 1
    Academic Journal

    Πηγή: Research and Practical Medicine Journal; Том 10, № 1 (2023); 57-67 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 57-67 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/860/538; https://www.rpmj.ru/rpmj/article/view/860/546; https://www.rpmj.ru/rpmj/article/downloadSuppFile/860/707; https://www.rpmj.ru/rpmj/article/downloadSuppFile/860/708; https://www.rpmj.ru/rpmj/article/downloadSuppFile/860/709; https://www.rpmj.ru/rpmj/article/downloadSuppFile/860/710; https://www.rpmj.ru/rpmj/article/downloadSuppFile/860/711; Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al.; BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019 May;20(5):663–673. https://doi.org/10.1016/s1470‑2045(18)30915‑x Erratum in: Lancet Oncol. 2019 Apr 2.; Yadav S, Xie H, Bin‑Riaz I, Sharma P, Durani U, Goyal G, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: propensity score matched analysis. Eur J Surg Oncol. 2019 Aug;45(8):1432–1438. https://doi.org/10.1016/j.ejso.2019.03.023; Tsilimigras DI, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A, et al. Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches. JAMA Surg. 2020 Sep 1;155(9):823–831. https://doi.org/10.1001/jamasurg.2020.1973; Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun. 2021;27:100354. https://doi.org/10.1016/j.ctarc.2021.100354; Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018 Jun;105(7):848–856. https://doi.org/10.1002/bjs.10676; Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al.; ABC‑02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273–1281. https://doi.org/10.1056/nejmoa0908721; Rizzo A, Brandi G. First‑line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC‑02 Trial: “And Yet It Moves!”. Cancer Treat Res Commun. 2021;27:100335. https://doi.org/10.1016/j.ctarc.2021.100335; Cho Y, Kim TH, Seong J. Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. Strahlenther Onkol. 2017 Aug;193(8):620–629. https://doi.org/10.1007/s00066‑017‑1128‑7; Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single‑center study. Ann Surg Oncol. 2013 Jan;20(1):318–324. https://doi.org/10.1245/s10434‑012‑2312‑8; Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, Cisplatin, and nab‑Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):824–830. https://doi.org/10.1001/jamaoncol.2019.0270; Ray CE Jr, Edwards A, Smith MT, Leong S, Kondo K, Gipson M, et al. Metaanalysis of survival, complications, and imaging response following chemotherapy‑based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2013 Aug;24(8):1218–1226. https://doi.org/10.1016/j.jvir.2013.03.019; Holster JJ, El Hassnaoui M, Franssen S, IJzermans JNM, de Jonge J, Mostert B, et al. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta‑Analysis. Ann Surg Oncol. 2022 Sep;29(9):5528–5538. https://doi.org/10.1245/s10434‑022‑11439‑x; https://www.rpmj.ru/rpmj/article/view/860

  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
    Academic Journal

    Περιγραφή αρχείου: application/pdf

    Relation: Борисова І. С. Фактори, що обумовлюють тяжкість пневмоній у хворих з порушеннями імунітету на фоні онкогематологічних захворювань / І. С. Борисова // Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії. – 2018. – Т. 18, вип. 1 (61). – С. 18–24.; https://repository.pdmu.edu.ua/handle/123456789/11034

  10. 10
  11. 11
  12. 12
    Academic Journal

    Πηγή: Complex Issues of Cardiovascular Diseases; № 3 (2013); 41-49 ; Комплексные проблемы сердечно-сосудистых заболеваний; № 3 (2013); 41-49 ; 2587-9537 ; 2306-1278 ; 10.17802/2306-1278-2013-3

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.nii-kpssz.com/jour/article/view/26/30; Значимость мультифокального атеросклероза для модификации шкалы риска отдаленной смертности GRACE у больных острым коронарным синдромом с подъемом сегмента ST / М. В. Зыков [и др.] // Атеросклероз. 2012. № 2. С. 11–17.; Шафранская К. С., Казачек Я. В., Кашталап В. В. Частота развития неблагоприятных сердечно-сосудистых событий у пациентов с мультифокальным атеросклерозом различной степени выраженности, подвергшихся коронарному шунтированию // Медицина в Кузбассе. 2011. № 3. С. 40–44.; ACC/AHA guidelines for the management of patients with unstable angina and non ST-elevation myocardial infarction: Executive summary and Recommendations. A report of the American College of Cardiology / American Heart Association task force on practice guidelines (committee on management of patients with unstable angina) / E. Braunwald [et al.] // Circulation. 2000. Vol. 102. P. 1193–1209.; Cavender M. A., Milford-Beland S., Roe M. T. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). // Am. J. Cardiol. 2009. Vol. 104, № 4. Р. 507–513.; Guidelines and Indications for Coronary Artery Bypass Graft Surgery. A Raport of the American Heart Association / American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Artery Bypass Graft Surgery) / J. W. Kirklin [et al.] // J. Am. Coll. Cardiol. 1991. Vol. 17. P. 543–560.; Impact of clinical and subclinical peripheral arterial disease in mid-term prognosis of patients with acute coronary syndrome / P. Morillas [et al.] / /Am. J. Cardiol. 2009. Vol. 104, № 11. Р. 1494–1498.; Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients / H. Suryapranata [et al.] // Heart. 2005. Vol. 91, № 5. Р. 641–645.; Jeger R. V., Pfisterer M. E. Primary PCI in STEMI – dilemmas and controversies: multivessel disease in STEMI patients. Complete versus Culprit Vessel revascularization in acute ST- elevation myocardial infarction // Minerva Cardioangiol. 2010. Vol. 87. P. 28–38.; Magnitude of and Risk Factors for In-Hospital and Postdischarge Stroke in Patients With Acute Coronary Syndromes. Findings From a Global Registry of Acute Coronary Events / A. Budaj [et al.] // Circulation. 2005. Vol. 111. Р. 3242–3247.; The general prognosis of patients with peripheral artery disease differs according to the disease localization / V. Aboyans [et al.] // J. Am. Coll. Cardiol. 2010. Vol. 55. Р. 898–903.; Toma, M. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial // Eur. Heart J. 2010. Vol. 8. Р. 1172–1177.; Word Health Organization. The Word Health Report: conquering, suffering, enriching humanity. Geneva: Word Health Organization, 2005. P. 53–57.

  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20